Back Hepatitis C

Hepatitis C

EASL 2012: MicroRNA Miravirsen Looks Safe and Effective for Genotype 1 Hepatitis C

Miravirsen, the first microRNA therapy for hepatitis C, was well-tolerated and demonstrated prolonged antiviral activity lasting past the end of dosing in a proof-of-concept study of previously untreated HCV genotype 1 patients presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

May Is Hepatitis Awareness Month

May is designated as Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of and encourage testing and care for viral hepatitis.alt

EASL 2012: Abbott Interferon-Free HCV Combinations Show Early Promise for Untreated Patients

Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naive patients presented last week at the 47th International Liver Congress (EASL 2012) in Barcelona.alt

EASL 2012: BI 201335 + BI 207127 + Ribavirin Shows Good Efficacy, Including Hepatitis C Patients with Cirrhosis

An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C patients, with favorable safety and efficacy among people with liver cirrhosis, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

EASL 2012: GS-7977 with Interferon/Ribavirin Cures Most Treatment-Naive Hepatitis C Patients in 12 Weeks

Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt

EASL 2012: Promising Findings for Therapeutic Hepatitis C Vaccine TG4040

An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) this week in Barcelona.alt

EASL 2012: Alisporivir + Ribavirin Is Effective for Hepatitis C, but Pancreatitis Remains a Concern

Alisporivir (formerly Debio 025) in interferon-free combinations cured more than 80% of patients with hepatitis C virus (HCV) genotype 2 or 3, researchers reported the 47th International Liver Congress (EASL 2012) last week in Barcelona. The drug has been put on hold, however, due to a small number of recipients developing life-threatening pancreas inflammation.alt

EASL 2012: Boceprevir a Useful Option for Patients Who Did Not Respond to Earlier Hepatitis C Therapy

A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40% and 68% in patients who did not respond to a previous course of hepatitis C therapy, data presented to the 47th International Liver Congress (EASL 2012) in Barcelona last week show.alt

EASL 2012: Simeprevir (TMC435) Improves Response Rates for Difficult-to-Treat Hepatitis C Patients

A combination of simeprevir -- better known as TMC435 -- plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according to a study presented at the 47th International Liver Congress (EASL 2012) last week in Barcelona.alt